Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 7 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
MITSUBISHI TANABE PHARMA Corporation currently has 10 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 7 distinct art units, indicating a range of pharmaceutical research. The company works with 9 distinct examiners to move these applications forward. Chang Yu Wang is the busiest examiner, handling 2 pending office actions.
The remaining actions are spread among other distinct examiners, showing examiner diversity for a portfolio of 10 pending matters. The presence of 7 distinct art units suggests that the company's biotechnology filings are technically diverse. With 9 distinct examiners involved, the prosecution strategy must account for many different individual approaches. Chang Yu Wang manages 2 of the active cases. The number of examiners is higher than the 7 distinct art units involved.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (20%) |
| §103 only | 2 (20%) |
| §102 only | 1 (10%) |
| §112 only | 2 (20%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, CHANG YU | 2 | 33.5% | +53.5% |
| PORTER, RACHEL L | 1 | 21.2% | +23.9% |
| ISMAIL, REHANA | 1 | 75.8% | +34.8% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 58.1% | +40.9% |
| GARTLAND, SCOTT D | 1 | 10.9% | +12.2% |
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
| DONOGHUE, BRITTNEY ERIN | 1 | 58.8% | +46.5% |
| PETRASH, HILARY ANN | 1 | 64.5% | +51.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17258741 | PREVENTION OR TREATMENT METHOD FOR PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTE DISORDER IS RECOGNIZED | PETRASH, HILARY ANN | 125d overdue |
| 18858801 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | PORTER, RACHEL L | — |
| 18715127 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | GARTLAND, SCOTT D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17258741 | PREVENTION OR TREATMENT METHOD FOR PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTE DISORDER IS RECOGNIZED | PETRASH, HILARY ANN | 125d overdue |
| 17757955 | AGENT FOR PREVENTING OR TREATING ACUTE-PHASE NEUROMYELITIS OPTICA | WANG, CHANG YU | 49d overdue |
| 17276106 | HUMAN ANTI-IL-33 MONOCLONAL ANTIBODY-CONTAINING PHARMACEUTICAL COMPOSITION | DONOGHUE, BRITTNEY ERIN | 46d overdue |
| 17792673 | AGENT FOR PREVENTION OR TREATMENT OF DIABETIC AUTONOMIC NEUROPATHY | MOSELEY II, NELSON B | 36d overdue |
| 18858801 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | PORTER, RACHEL L | — |
| 18872328 | SOLID FORMS OF RXFP1 MODULATORS | ISMAIL, REHANA | — |
| 17442798 | COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR MODULATING EXPRESSION OF DUX4 | SULLIVAN, STEPHANIE LAUREN | — |
| 18715127 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | GARTLAND, SCOTT D | — |
| Art Unit | Apps |
|---|---|
| 1675 | 3 |
| 1625 | 1 |
| 1635 | 1 |
| 3685 | 1 |
| 1623 | 1 |
| 1642 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18858801 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | PORTER, RACHEL L | — | §101§102§103§112 | Non-Final OA | — | Pending | Jul 23, 2025 |
| 18872328 | SOLID FORMS OF RXFP1 MODULATORS | ISMAIL, REHANA | 1625 | §112 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 17442798 | COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR MODULATING EXPRESSION OF DUX4 | SULLIVAN, STEPHANIE LAUREN | 1635 | §112 | Final Rejection | — | Pending | Aug 15, 2024 |
| 18715127 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | GARTLAND, SCOTT D | 3685 | §101§102§103§112 | Final Rejection | — | Pending | May 31, 2024 |
| 18172449 | COMPOUNDS AND THEIR USE | LEE, WILLIAM Y | 1623 | §102§112DP | Non-Final OA | — | Pending | Feb 22, 2023 |
| 17792673 | AGENT FOR PREVENTION OR TREATMENT OF DIABETIC AUTONOMIC NEUROPATHY | MOSELEY II, NELSON B | 1642 | §103 | Non-Final OA | 36d overdue | Pending | Jul 13, 2022 |
| 17792574 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DEMENTIA | WANG, CHANG YU | 1675 | DP | Non-Final OA | — | Pending | Jul 13, 2022 |
| 17757955 | AGENT FOR PREVENTING OR TREATING ACUTE-PHASE NEUROMYELITIS OPTICA | WANG, CHANG YU | 1675 | §102 | Non-Final OA | 49d overdue | Pending | Jun 24, 2022 |
| 17276106 | HUMAN ANTI-IL-33 MONOCLONAL ANTIBODY-CONTAINING PHARMACEUTICAL COMPOSITION | DONOGHUE, BRITTNEY ERIN | 1675 | §103 | Final Rejection | 46d overdue | Pending | Mar 12, 2021 |
| 17258741 | PREVENTION OR TREATMENT METHOD FOR PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTE DISORDER IS RECOGNIZED | PETRASH, HILARY ANN | 1644 | §102§103§112Other | Final Rejection | 125d overdue | Pending | Jan 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial